|
|
Article: BioMedEcon Reports Six Times Higher Psychiatric Medication Costs among Patients with Obsessive-Compulsive Disorder Compared to Patients with Depression.
- Article from:
- Business Wire
- Article date:
- September 2, 2008
|
Copyright informationCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Results show significantly higher per-patient, median costs for psychiatric medications among newly-diagnosed patients with OCD versus patients with depression
MOSS BEACH, Calif. -- BioMedEcon Group, a leading provider of health economics and outcomes research, presented findings of a unique nine-year retrospective claims analysis that compared the per-patient, median healthcare costs of newly-diagnosed patients with obsessive-compulsive disorder (OCD) to matched patients with depression. The study, supported by Jazz Pharmaceuticals, Inc., was presented at the European College of Neuropsychopharmacology (ECNP) 21st Congress on Sept. 1 in Barcelona, Spain.
...
Related newspaper, magazine, and journal articles:
|